Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Novotech and Endpoints News Collaborate on Webinar Series about the Asia-Pacific Clinical Trial Landscape

Novotech and Endpoints News Collaborate on Webinar Series about the Asia-Pacific Clinical Trial Landscape

May 25,2020

The leading Asia-Pacific biotech specialist CRO Novotech is collaborating with the prestigious biotech and pharma media platform Endpoints News for a series of webinars about the advantages of conducting clinical trials in the Asia-Pacific.

Endpoints Publisher Arsalan Arif will moderate sessions including Novotech executives, key opinion leaders from the region and biotech sponsors with Asia Pacific experience. Participants include:

  • Yooni Kim, Executive Director, Asia Operations at Novotech
  • Alejandro Ricart M.D. VP Clinical Development at TG Therapeutics
  • Daniela Caiazza, Director Clinical Operations ANZ at Novotech
  • Hannah Tarrant, Project Director at Novotech
  • Kristyn Munro, Director, Business Development Operations at Novotech

Arsalan Arif said he was pleased to offer readers new insights into Asia-Pacific clinical opportunities.

“As we return to business under a pandemic, biotechs are looking for places they can reliably conduct trials. Asia-Pacific is clearly a top destination of interest and having the Novotech team who can share their first-hand experience with sites, research teams, and sponsors in the Asia-Pacific region will be valuable for our subscribers who are reviewing their next trial locations.”

The first webinar on 8 June, 2020 is titled:

Clinical Trial Continuity in Asia-Pacific during the COVID-19 Pandemic

Click here to register

Novotech CEO Dr. John Moller said “Many countries in Asia Pacific have managed the COVID-19 pandemic extremely effectively, and sites have adapted quickly to ensure trial continuity. This presents an opportunity for sponsors to shift their activity from the US and Europe to Asia to ensure their trials stay on track.”

The webinar will also cover:

  • The status of COVID 19 in the region and the factors that have driven the relatively low spread
  • Regulatory guidance and acceptability of remote monitoring and de-centralized clinical trials in Asia-Pacific
  • Risk management strategies

Novotech says the Asia-Pacific region is highly attractive for biotechs running clinical studies, with its streamlined regulatory environment and advanced medical infrastructure.

Each year Novotech manages more than 200 clinical trials and projects in the region, which boasts large and engaged patient populations and world first medical and research teams and facilities.

Biotech companies are currently initiating more clinical trials in Asia and Australia/New Zealand than in North America. Novotech recently released new data from GlobalData showing since 1 March, biotech companies have initiated about 10% more trials in Asia-Pacific than in North America. In addition, since 1 March, biotech companies initiated twice as many Phase 1 trials in Asia-Pacific than in North America.

Novotech also has long-term Partnerships with the leading medical institutions throughout the Asia-Pacific giving Novotech clients unique access to some of the top researchers, investigators and key opinion leaders.